172 results on '"Ossendorp, Ferry"'
Search Results
2. Therapeutic liposomal combination to enhance chemotherapy response and immune activation of tumor microenvironment
3. Immune checkpoint inhibition combined with targeted therapy using a novel virus-like drug conjugate induces complete responses in a murine model of local and distant tumors
4. Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation
5. OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum
6. Effective combination of liposome-targeted chemotherapy and PD-L1 blockade of murine colon cancer
7. The role of pigmentation in tumor treatment with the investigational virus-like drug conjugate belzupacap sarotalocan in an in vitro and in vivo murine model
8. Quantification of Lipid and Peptide Content in Antigenic Peptide-loaded Liposome Formulations by Reversed-phase UPLC using UV Absorbance and Evaporative Light Scattering Detection
9. A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection
10. M1-derived extracellular vesicles enhance photodynamic therapy and promote immunological memory in preclinical models of colon cancer
11. Lipid A analog CRX-527 conjugated to synthetic peptides enhances vaccination efficacy and tumor control
12. Combinatorial therapeutic approaches of photodynamic therapy and immune checkpoint blockade for colon cancer treatment
13. Upconversion nanoparticle platform for efficient dendritic cell antigen delivery and simultaneous tracking
14. Measuring the Antitumor T-Cell Response in the Context of Photodynamic Therapy
15. Combination of Photodynamic Therapy and Immune Checkpoint Blockade
16. Combination of Photodynamic Therapy and Therapeutic Vaccination
17. Tumor Pigmentation Does Not Affect Light-Activated Belzupacap Sarotalocan Treatment but Influences Macrophage Polarization in a Murine Melanoma Model
18. T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
19. Multiantigen pan-sarbecovirus DNA vaccines generate protective T cell immune responses
20. Dual‐Targeting Nanoliposome Improves Pro‐inflammatory Immunomodulation of the Tumor Microenvironment
21. Genome-wide CRISPR screens define determinants of epithelial-mesenchymal transition mediated immune evasion by pancreatic cancer cells
22. In Vitro Testing of the Virus-Like Drug Conjugate Belzupacap Sarotalocan (AU-011) on Uveal Melanoma Suggests BAP1-Related Immunostimulatory Capacity
23. Data from CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy
24. Data from Efficient Eradication of Established Tumors in Mice with Cationic Liposome-Based Synthetic Long-Peptide Vaccines
25. Figure S1 from CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy
26. Supplementary Figure 2 from Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand–Peptide Conjugates
27. Supplementary Figure Legends from Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand–Peptide Conjugates
28. Data from Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand–Peptide Conjugates
29. Supplementary Tables 1 and 2 and Supplementary Figures 1 through 7 from Efficient Eradication of Established Tumors in Mice with Cationic Liposome-Based Synthetic Long-Peptide Vaccines
30. Figure legends from CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy
31. Supplementary Figure 1 from Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand–Peptide Conjugates
32. Dual‐Targeting Nanoliposome Improves Proinflammatory Immunomodulation of the Tumor Microenvironment.
33. Chapter Two - How B cells drive T-cell responses: A key role for cross-presentation of antibody-targeted antigens.
34. Supplementary Figure 2 from Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell–Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects
35. CCR Translation for This Article from Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell–Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects
36. Supplementary Figure Legend from Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell–Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects
37. Supplemental figure 3 from Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death
38. Supplementary Figure 1 from Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell–Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects
39. Supplementary Figure 3 from Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell–Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects
40. Supplemental figure 4 from Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death
41. Data from Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death
42. Supplemental Video 2 from Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death
43. Supplemental figure 2 from Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death
44. supplementary legend from Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death
45. Supplemental Video 1 from Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death
46. Supplemental Video 3 from Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death
47. Supplemental figure 1 from Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death
48. Supplemental Video 4 from Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death
49. MC38 colorectal tumor cell lines from two different sources display substantial differences in transcriptome, mutanome and neoantigen expression
50. Tumor-nonspecific vaccines improve the efficacy of CD3 bispecific antibody therapy in solid tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.